Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04442581 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04442581 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 2 participants.
The verdict
NCT04442581, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase II trial studies how well cabozantinib and pembrolizumab work for the first-line treatment of patients with liver cancer who are not eligible for local therapy (i.e. advanced stage). Cabozantinib may stop the growth of tumor cells by blocking some cell surface receptors and signaling pathways inside the tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer. Giving cabozantinib and pembrolizumab together may work better in treating patients with advanced liver cancer compared to cabozantinib or pembrolizumab alone.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Cabozantinib S-malate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-04-20 |
| Est. Completion | 2022-03-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04442581
The ClinicalTrials.gov registry entry for NCT04442581 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04442581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04442581 about?
NCT04442581 is a clinical study titled "Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer". This phase II trial studies how well cabozantinib and pembrolizumab work for the first-line treatment of patients with liver cancer who are not eligible for local therapy (i.e. advanced stage). Cabozantinib may stop the growth of tumor cells by blocking some cell surface receptors and signaling path...
What is the current status of trial NCT04442581?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2021-04-20. Estimated completion is 2022-03-08.
What interventions are being tested in trial NCT04442581?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Cabozantinib S-malate (DRUG).
Who is sponsoring clinical trial NCT04442581?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.